CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,036 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01383421
NCT01383421N/ACompleted

A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis (PASSION Study)

AbbVie (prior sponsor, Abbott)·observational·Posted Jun 28, 2011·Updated Jun 26, 2017

In Brief

An observational study for Rheumatoid Arthritis. Completed, enrolled 1,036 participants.

Detailed Summary

This study is a non-confirmatory post-marketing observational study to explore and describe the effectiveness of adalimumab on rheumatoid arthritis (RA) treatment course and participant satisfaction over time in context with utilization of a patient support program (PSP). The core elements of the PSP were call centers (in and outbound)/hotlines, nursing services, starter packs, provision of educational materials (print and digital) regarding RA and adalimumab, and injection guides. Other elements of the PSP, which varied between countries, included (but were not limited to) refill reminders, email contacts, support groups, and newsletters.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2011
Enrollment StartSep 1, 2011
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.0 years ago